IRMD Q2 2025: 12% ASP Lift on 3870 Pump Unlocks $100M Run Rate Trajectory
Eratomed’s FDA-cleared 3870 pump, with a 12% higher average selling price (ASP), primes the business for a major upgrade cycle and a step-change in growth. Legacy 3860 pumps continue to drive robust results, but management’s visibility on backlog and a methodical launch plan for the new device underpin confidence in surpassing $100 million in annual revenue by 2026. Investors should watch the pace of replacement sales and margin expansion as the next phase unfolds.
Summary
- Upgrade Cycle Acceleration: 3870 pump FDA clearance sets up a multi-year replacement wave.
- Margin Expansion Levers: Higher ASP and modernized design support gross and operating margin upside.
- Backlog Visibility: Record backlog and controlled legacy pump tapering de-risk near-term execution.
Performance Analysis
Eratomed posted its 16th consecutive record quarter, with revenue rising 14% year-over-year to $20.4 million, driven by broad-based strength across MRI IV pumps, monitoring, disposables, and services. The MRI-compatible IV infusion pump line, the company’s core product, delivered $8.2 million, up 19%, while patient monitoring systems rose 9% to $5.9 million. Disposables, a key recurring revenue stream, grew 14%, reflecting higher device utilization. Domestic sales now comprise 89% of total revenue, up from 86%, as international sales dipped, a dynamic management attributes to timing rather than demand loss.
Gross margin held steady at 78%, benefiting from inventory build ahead of the new facility opening, while operating expenses grew at a slower pace than revenue, supporting 21% growth in operating income. Cash flow from operations advanced 17% to $7.7 million, with free cash flow absorbing elevated capital expenditures tied to the new headquarters. The company’s balance sheet remains strong, with $53 million in cash and ample capacity to fund commercial ramp and dividend commitments.
- Legacy Pump Strength: 3860 pump shipments remain robust, with management controlling the transition pace to the new 3870 model.
- Disposables Drive Utilization: Double-digit disposables growth signals higher installed base activity and recurring revenue durability.
- Operating Leverage: Expense discipline and scale effects are translating revenue growth into outsized profit gains.
Facility investment and a controlled commercial rollout of the 3870 pump set the stage for accelerated growth, with margin expansion likely as higher ASPs flow through the P&L in 2026 and beyond.
Executive Commentary
"With this long-awaited and hard-fought FDA action, the road ahead for Aradamid is clear and wide. Since the founding of Aradamid 20 years ago, this clearance and the sales growth that the new pump will ignite will prove to be a seminal event."
Roger Soucy, President and Chief Executive Officer
"Gross profit was 16 million, up 14% from 14 million in Q2 of 2024, with a gross margin of 78%, consistent with the prior year. The strong margin performance was supported by increased overhead absorption as we built inventory ahead of the new facility's opening."
Jack Glenn, Chief Financial Officer
Strategic Positioning
1. 3870 Pump Launch: Unlocking Replacement and Expansion
The FDA-cleared 3870 pump, featuring a modern user interface and enhanced usability, targets both the replacement of over 6,200 five-plus-year-old legacy pumps in the U.S. and expansion into new accounts that previously resisted adoption. Management’s plan is to add 1,000 annual replacement channels to the existing 1,000 baseline, with upside from greenfield conversions.
2. ASP and Margin Uplift: Pricing Power Materializes
Initial pricing models for the 3870 pump indicate a 12% ASP premium over the outgoing model. This, coupled with design-driven cost efficiencies, should translate directly into higher gross and operating margins, with management signaling that margin gains may outpace ASP growth as the mix shifts toward the new device.
3. Controlled Transition and Backlog Management
Legacy 3860 pump sales remain strong, with the sales force instructed not to actively market the 3870 until December. This approach maximizes near-term revenue and prevents premature cannibalization, while a record backlog in both pumps and monitors provides visibility and de-risks the transition period.
4. Facility Investment: Capacity for Scale
Completion of the new headquarters and manufacturing facility positions Eratomed to support higher production volumes and operational efficiency, with final construction costs of $12.6 million nearly complete and only minor payments remaining.
5. Dividend Commitment and Capital Allocation
The board reaffirmed its $0.17 per share quarterly dividend, reflecting confidence in cash generation even as the company invests for growth. This capital allocation signals a balance between shareholder returns and reinvestment in the business.
Key Considerations
Eratomed’s Q2 results and commentary underscore a pivotal moment as the company transitions from a maturing legacy product cycle to a new era of growth fueled by the 3870 pump upgrade wave and margin expansion. The following considerations will shape the investment case in the coming quarters:
Key Considerations:
- Upgrade Wave Timing: The pace at which hospitals and imaging centers replace legacy 3860 pumps with the 3870 will determine the revenue ramp and margin profile in 2026.
- Backlog Fulfillment: A five to six month pump backlog provides near-term revenue visibility, but execution risk exists in scaling production and managing customer transitions.
- Disposables Attach Rate: Sustained double-digit growth in disposables will be a key indicator of installed base health and recurring revenue stability.
- Margin Realization: The ability to capture the forecasted ASP premium and drive cost leverage as volumes increase will be critical to delivering on profit guidance.
- International Sales Recovery: A rebound in international markets, which declined this quarter, could add incremental upside if execution improves.
Risks
Key risks include potential delays or execution missteps in the 3870 pump rollout, as the transition from legacy to next-generation devices requires coordinated sales, manufacturing, and customer support. Tariff exposure remains a watchpoint as pre-tariff inventories are depleted, and international market softness could persist if not addressed. Any operational hiccups in the new facility or slower-than-expected replacement demand could pressure revenue and profit targets.
Forward Outlook
For Q3 2025, Eratomed guided to:
- Revenue of $20.5 million to $20.9 million (12%-14% YoY growth)
- GAAP diluted EPS of $0.41 to $0.45, Non-GAAP diluted EPS of $0.45 to $0.49 (10%-12% YoY growth)
For full-year 2025, management raised guidance:
- Revenue of $80 million to $82.5 million (up from $78 million to $82 million prior)
- GAAP EPS of $1.60 to $1.70, Non-GAAP EPS of $1.76 to $1.86
Management highlighted:
- Strong legacy pump and monitor backlog sustaining growth through the transition
- Facility move causing short-lived operational inefficiencies, but not impacting overall trajectory
Takeaways
Investors should recognize that Eratomed is entering a new growth phase, with the 3870 pump unlocking both a sizable replacement cycle and incremental ASP-driven margin expansion. Operational discipline, a sequenced rollout, and a robust backlog reduce near-term risk, while the potential for greenfield adoption offers upside not yet reflected in guidance.
- Upgrade Cycle Inflection: The 3870 pump’s FDA clearance and premium pricing will drive a step-change in revenue and margin as replacements accelerate through 2026.
- Margin Upside Catalyst: Higher ASP and improved design economics should deliver gross and operating margin expansion as the mix shifts to the 3870.
- Execution Watchpoint: Investors should monitor the pace of replacement sales, backlog conversion, and any signs of operational friction as the facility transition completes and the new pump ramps.
Conclusion
Eratomed’s Q2 results confirm a business at the cusp of a major upgrade-driven growth cycle, with a clear path to surpassing $100 million in annual revenue and expanding margins. The next 18 months will test execution, but the strategic foundation is solid and the commercial opportunity is significant.
Industry Read-Through
Eratomed’s experience highlights the power of FDA-cleared innovation and planned upgrade cycles in medtech, especially for niche device categories with aging installed bases. The deliberate transition strategy and ASP leverage provide a blueprint for peers managing generational product shifts. For competitors and suppliers, the lengthening backlog and premium pricing signal robust demand for MRI-compatible infusion and monitoring systems. The facility investment and dividend discipline also underscore the importance of balancing reinvestment with shareholder returns as medtech companies scale new platforms.